尼罗罗非鱼抗[具体病原体1]和[具体病原体2]二价疫苗：实验室阶段及大规模研究

Bivalent Vaccine against and in Nile Tilapia (): A Laboratory-Phase and Large-Scale Study.

作者信息

Rivas Açucena Veleh, Dos Santos Angelo Gabriel Vidal, de Souza Adrieli Barboza, Bueno Junior Gilson, de Souza Gabriela Fernandes, de Souza Estevam Martins, de Carvalho Nunes Louisiane, Viana Kelvinson Fernandes

机构信息

Vaccine Development Technology Laboratory, Latin American Institute of Life and Nature Sciences, Federal University of Latin American Integration, Foz do Iguaçu 85870-650, Brazil.

Alquimia Pescados, Foz do Iguaçu 85870-180, Brazil.

出版信息

Animals (Basel). 2023 Oct 26;13(21):3338. doi: 10.3390/ani13213338.

DOI:10.3390/ani13213338

PMID:37958093

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10650067/

Abstract

One of the main factors limiting tilapia's production is the occurrence of infections caused by and species. This work intended to evaluate a bivalent vaccine against and by intraperitoneal (i.p) administration in Nile tilapia () in Brazil. The study was carried out in two phases: one in the laboratory, on a small scale, and from the results obtained, the study was expanded to a large scale in a production system in cages. The vaccine proved to be safe and effective in laboratory tests, with a vaccine efficacy (VE) of 93.66%. However, in large-scale tests with 12,000 tilapias, the VE was 59.14%, with a better food conversion ratio (1.54 kg) in the vaccinated group compared to the control group (1.27 kg). These results corroborate the efficiency of this tested vaccine; however, they indicate the need for field tests to attest to real protection.

摘要

限制罗非鱼产量的主要因素之一是由[具体物种1]和[具体物种2]引起的感染。本研究旨在通过腹腔注射（i.p）评估一种针对[具体物种1]和[具体物种2]的二价疫苗对巴西尼罗罗非鱼（Oreochromis niloticus）的效果。该研究分两个阶段进行：第一阶段在实验室小规模开展，根据所得结果，研究扩大至网箱养殖生产系统的大规模试验。疫苗在实验室测试中被证明是安全有效的，疫苗效力（VE）为93.66%。然而，在对12,000尾罗非鱼进行的大规模测试中，疫苗效力为59.14%，与对照组（1.27千克）相比，接种疫苗组的饲料转化率更高（1.54千克）。这些结果证实了该测试疫苗的有效性；然而，这表明需要进行实地测试以证明其实际保护效果。